Supplement: Key variables to be collected

### Key variables to be collected for each site

**Laboratory and NGS test details**
- Number of NGS tests performed per month
- Laboratory accreditation type, if applicable
- Type of NGS test (e.g. hotspot, CGP, WES, WGS)
- NGS technique (e.g. amplicon, hybrid capture)
- If a panel was used, number and names of genes analyzed
- For commercial or lab-developed tests, information on analytic and clinical validation

### Key variables to be collected for each participant

**Medical history**
- Prior cancer history (if any)
- Initial diagnosis details of current cancer (e.g. cancer diagnosis and date of diagnosis, stage)
- Prior cancer biomarker results
- Past outcome assessment for current cancer and criteria used (e.g. RECIST, if applicable)
- Details of past treatment and therapies
- Past major procedures

**Medical information at baseline** (collected within 3 months of NGS test order)
- Socio-demographic information
- Family history of cancer
- Comorbidities
- Current cancer details (e.g. stage)
- Clinical measures (e.g. performance status)
- NGS sample details and NGS test results
- Cancer biomarker results
- Current cancer treatments and therapies, including means of access
- Diagnostic procedures
- Physician and MTB decision-making

**Medical information at follow-ups** (collected at least every 6 months)
- Changes in information collected at baseline
- Additional NGS test results
- Additional cancer biomarker results
- New/ongoing cancer treatments, therapies, and major procedures, including means of access
- Reason(s) for treatment discontinuation, if applicable
- Date and means of assessing disease progression
- Date of death
- Rationale for additional NGS testing and decision-making
- Adverse events that have a direct clinical consequence on the administered therapies, patients, or occurrence of pregnancies

**Abbreviations:** CGP, comprehensive genomic profiling; MTB, molecular tumor board; NGS, next-generation sequencing; RECIST, Response Evaluation Criteria In Solid Tumours; WES, whole-exome sequencing; WGS, whole-genome sequencing.
WAYFIND-R: Delivering a high-quality real-world data (RWD) global registry of patients diagnosed with a solid tumor and profiled with next-generation sequencing (NGS)

Christophe Le Tourneau, Allan Hackshaw, Jean-Yves Blay, Jan Geissler, Clare Turnbull, Camille Perret, Olga Skatkova, Martina von Meyenn, Rodrigo Dienstmann

Supplement: Conflicts of interest

CLT has received grants/contracts from MSD, has received travel expenses from MSD, BMS, and AstraZeneca, has received honoraria from and performed a consulting/advisory role for BMS, MSD, Merck Serono, Roche, Nanobiotix, GSK, Rakuten, Seattle Genetics, and AstraZeneca, and has been paid by Roche as an external consultant. AH has held stock in Illumina and ThermoFisher (sold in 2020), has received grants/contracts from Roche, MSD, Takeda, BMS, Boehringer Ingelheim, and Celgene (several pharmaceutical companies provided research funding for UCL-sponsored trials), has received honoraria from AbbVie, Boehringer Ingelheim, Takeda, AstraZeneca, Daiichi Sankyo, Merck Serono, Merck/MSD, UCB, and Roche for delivering general education/training in clinical trials, and has performed a consulting/advisory role for AbbVie, Roche, and GRAIL, Inc. J-YB has received grants/contracts from Novartis, Bayer, GSK, Pfizer, Deciphera, Roche, BMS, MSD, and AstraZeneca, has a leadership role with Innate Pharma, has received honoraria from Novartis, Bayer, Pfizer, Deciphera, and Roche, and has performed a consulting/advisory role for Novartis, Bayer, GSK, Pfizer, Deciphera, Roche, BMS, MSD, and AstraZeneca. JG has received grants/contracts from Novartis, Incyte, BMS, Pfizer, and Takeda, has received travel expenses from Amgen, Alnylam, BioMarin, Novartis, Pfizer, Roche, Servier, and UCB, and has performed a consulting/advisory role for Alnylam, Bayer, Boehringer Ingelheim, BioMarin, Daiichi Sankyo, Gilead, Janssen, Novartis, Pfizer, Roche, Servier, Sanofi, Sobi, and UCB. CT has received honoraria from AstraZeneca, Roche, and Pfizer, has performed a consulting/advisory role for AstraZeneca and Roche, and has attended a speaker’s bureau for AstraZeneca. CP is an employee of and holds stocks in F. Hoffmann-La Roche Ltd. OS is an employee of and holds stocks in F. Hoffmann-La Roche Ltd. MvM is an employee of and holds stocks in F. Hoffmann-La Roche Ltd. RD is an employee of Oncoclínicas Grupo, has business ownership in Trialing, has received a grant/contract from Merck, has performed a consulting/advisory role for Roche and Boehringer Ingelheim, and has attended speakers’ bureaus for Roche, Ipsen, Sanofi, MSD Oncology, Servier, Amgen, and Libbs.